Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2025 Filed Nov 26, 2025 18:50 UTC |
Murali RamachandranVP of Research and Development
|
GrantCOMMON STOCK | 152,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025224 · ownership.xml · nonDerivative · entry 1 Murali Ramachandran · CIK 0001870016 · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 299,529 F1 · shares: Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of (1) 142,191 shares of common stock and (2) 157,338 RSUs which remain subject to vesting. Read SEC document |
| October 08, 2025 Filed Nov 26, 2025 22:26 UTC |
Singhvi RahulDirector
|
GrantCOMMON STOCK | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025203 · ownership.xml · nonDerivative · entry 1 Singhvi Rahul · CIK 0001322731 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,204 F1 · shares: Represents 19,084 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of 49,204 RSUs which remain subject to vesting. Read SEC document |
| October 08, 2025 Filed Nov 26, 2025 17:24 UTC |
Yu John SDirector · CEO and Chairman · 10% owner
|
GrantCOMMON STOCK | 190,840 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025197 · ownership.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 230,105 F1 · shares: Represents 190,840 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 190,840 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of (1) 34,599 shares of common stock (2) 195,506 RSUs which remain subject to vesting. Read SEC document |
| October 08, 2025 Filed Nov 26, 2025 17:27 UTC |
Keyoung Hansoo MichaelDirector
|
GrantCOMMON STOCK | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025205 · ownership.xml · nonDerivative · entry 2 Keyoung Hansoo Michael · CIK 0001824764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,084 F3 · shares: Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F4 · balance_after: Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting. Read SEC document |
| October 08, 2025 Filed Nov 26, 2025 17:24 UTC |
Samuelson DougChief Financial Officer
|
GrantCOMMON STOCK | 152,672 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025198 · ownership.xml · nonDerivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 293,039 F1 · shares: Represents 152,672 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 152,672 RSUs are scheduled to vest in full on the first anniversary of the grant date. F2 · balance_after: Consists of (1) 140,367 shares of common stock and (2) 152,672 RSUs which remain subject to vesting. Read SEC document |
| October 08, 2025 Filed Dec 23, 2025 06:03 UTC |
Bae Hyun W.Director
|
GrantCOMMON STOCK | 19,084 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028895 · ownership.xml · nonDerivative · entry 2 Bae Hyun W. · CIK 0001988551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,370 F3 · shares: Represents 19,084 RSUs issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date. F4 · balance_after: Consists of (i) 54,286 shares of common stock and (ii) 19,084 RSUs which remain subject to vesting. Read SEC document |
| October 08, 2025 Filed Dec 30, 2025 16:10 UTC |
Bhowmick NeilChief Scientific Officer
|
GrantCOMMON STOCK | 171,756 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-029601 · ownership.xml · nonDerivative · entry 1 Bhowmick Neil · CIK 0001872210 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,311,739 F1 · shares: Represents 171,756 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 171,756 RSUs are scheduled to vest on the on the first anniversary of the grant date which is October 8, 2026. F2 · balance_after: Consists of (1) 1,135,317 shares of common stock and (2) 176,422 RSUs which remain subject to vesting. Read SEC document |
| September 16, 2025 Filed Nov 26, 2025 17:27 UTC |
Keyoung Hansoo MichaelDirector
|
GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-025205 · ownership.xml · nonDerivative · entry 1 Keyoung Hansoo Michael · CIK 0001824764 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 F1 · shares: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO. F2 · balance_after: Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. Read SEC document |
| September 16, 2025 Filed Dec 23, 2025 06:03 UTC |
Bae Hyun W.Director
|
GrantCOMMON STOCK | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-028895 · ownership.xml · nonDerivative · entry 1 Bae Hyun W. · CIK 0001988551 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,286 F1 · shares: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and vest annually in three substantially equal installments commencing on the anniversary date of the IPO. F2 · balance_after: Consists of (i) 47,620 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting. Read SEC document |
| January 01, 2025 Filed Feb 24, 2025 18:52 UTC |
Murali RamachandranVP of Research and Development
|
GrantCOMMON STOCK | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-008106 · ownership.xml · nonDerivative · entry 1 Murali Ramachandran · CIK 0001870016 · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,057 F1 · shares: Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. F2 · balance_after: Consists of (1) 137,724 shares of common stock and (2) 9,333 RSUs which remain subject to vesting. Read SEC document |
| January 01, 2025 Filed Feb 24, 2025 18:51 UTC |
Yu John SDirector · CEO and Chairman · 10% owner
|
GrantCOMMON STOCK | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-008105 · ownership.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,355,838 F1 · shares: Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. F2 · balance_after: Consists of (1) 5,346,504 shares of common stock and (2) 9,334 RSUs which remain subject to vesting. Read SEC document |
| January 01, 2025 Filed Apr 7, 2025 08:30 UTC |
Bhowmick NeilChief Scientific Officer
|
GrantCOMMON STOCK | 14,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-002927 · ownership.xml · nonDerivative · entry 1 Bhowmick Neil · CIK 0001872210 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,139,983 F1 · shares: Represents 14,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan. The 14,000 RSUs are scheduled to vest in one third increments on each of 01/01/2025, 09/16/2025, and 09/16/2026. Accordingly, 4,667 RSUs have vested as of the date hereof. F2 · balance_after: Consists of (1) 1,130,650 shares of common stock and (2) 9,333 RSUs which remain subject to vesting. Read SEC document |
| November 25, 2024 Filed Nov 25, 2024 20:30 UTC |
Murali RamachandranVP of Research and Development
|
PurchaseCOMMON STOCK | 200 | $1.59 | $318.00 |
DisclosureSEC source: 0001493152-24-047695 · ownership.xml · nonDerivative · entry 1 Murali Ramachandran · CIK 0001870016 · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,057 Read SEC document |
| November 22, 2024 Filed Nov 25, 2024 06:03 UTC |
Samuelson DougChief Financial Officer
|
PurchaseCOMMON STOCK | 2,500 | $1.50 | $3,750.00 |
DisclosureSEC source: 0001493152-24-047526 · ownership.xml · nonDerivative · entry 1 Samuelson Doug · CIK 0001943326 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,796 Read SEC document |
| November 20, 2024 Filed Nov 21, 2024 21:53 UTC |
Yu John SDirector · CEO and Chairman · 10% owner
|
PurchaseCOMMON STOCK | 4,000 | $1.44 | $5,760.00 |
DisclosureSEC source: 0001493152-24-047261 · ownership.xml · nonDerivative · entry 1 Yu John S · CIK 0001550545 · Director · CEO and Chairman · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,341,837 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.